Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Cynata Therapeutics (ASX:CYP), a stem cell therapy developer, fell after disappointing clinical results. In June 2026, SG Hiscock reported Cynata was a significant detractor after disappointing readouts from two key clinical trials, which weighed heavily on the share price. Cynata Therapeutics operates in the Healthcare sector within the Biotechnology industry, and Thesis Tracker has captured 1 comment from 1 fund manager, SG Hiscock & Company. Headquartered in Melbourne, Cynata Therapeutics develops and commercialises induced pluripotent stem cell-derived mesenchymal stem cell therapies using its proprietary Cymerus platform, which allows consistent, large-scale manufacturing of cell therapies, and has been testing its products in trials for conditions including acute graft-versus-host disease, osteoarthritis and kidney transplantation, alongside partnerships with pharmaceutical companies.
Company figures as of 15 Oct 2026. For information only.
Fund managers including SG Hiscock & Company have invested in Cynata Therapeutics Ltd (ASX:CYP).
The available commentary does not highlight specific opportunities, though Cynata's Cymerus platform offers scalable stem cell manufacturing technology.
SG Hiscock notes disappointing readouts from two key clinical trials, which significantly reduced the company's value.
Cynata Therapeutics Limited develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Lead candidate CYP-001 has completed Phase 2 trials for graft versus host disease. CYP-004, targeting osteoarthritis, is in Phase 3 trials. CYP-006TK is a polymer-coated silicon wound dressing for diabetic wounds. A Diabetic Foot Ulcer candidate has completed Phase 1 trials for non-healing foot and lower-limb wounds, while Cohort 1 has completed Phase 1/2 trials for kidney transplant treatment. Cynata holds a license arrangement with Fujifilm. Formerly Eco Quest Limited, the company was renamed in October 2013, incorporated in 2003, and is headquartered in Cremorne, Australia.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.